Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Lymphoma 24Leukemia 18Sarcoma 17Neuroblastoma 13Central Nervous System Neoplasms 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Hodgkin Disease 9Breast Neoplasms 9Brain Neoplasms 9Burkitt Lymphoma 7Malignant mesenchymal tumor 6Lymphoma, Large B-Cell, Diffuse 6Leukemia, Myeloid, Acute 6Leukemia, Monocytic, Acute 6Rhabdomyosarcoma 5Ovarian Neoplasms 5Multiple Myeloma 5Leukemia, Myelomonocytic, Acute 5Leukemia, Megakaryoblastic, Acute 5Leukemia, Erythroblastic, Acute 5Kidney Neoplasms 5Testicular Neoplasms 4Teratoma 4Neutropenia 4Neuroectodermal Tumors, Primitive, Peripheral 4Medulloblastoma 4Lung Neoplasms 4Leukemia, Biphenotypic, Acute 4Endometrial Neoplasms 4Dendritic Cell Sarcoma, Interdigitating 4

Interventions

Gemcitabine 2Docetaxel 2pegfilgrastim 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Recurrent Uterine Corpus Sarcoma × Filgrastim × Clear all
NCT00031629 2016-12-08

Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus

GOG Foundation

Phase 2 Completed
51 enrolled
GynecologicSarcoma

Recurrent Uterine Corpus Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡